CeleCor files final FDA NDA section for heart-attack drug zalunfiban

The submission follows positive Phase 3 CeleBrate data presented in November, as the company also names Michael Moye chief commercial officer.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.